
-
Garcia beaten by Romero in return from doping ban
-
Inflation, hotel prices curtail Japanese 'Golden Week' travels
-
Trump's next 100 days: Now comes the hard part
-
Mexican mega-port confronts Trump's tariff storm
-
Trump's tariffs bite at quiet US ports
-
Ryu stretches lead at LPGA Black Desert Championship
-
Singapore votes with new PM seeking strong mandate amid tariff turmoil
-
Five things to know about the Australian election
-
Scheffler fires 63 despite long delay to lead CJ Cup Byron Nelson
-
Israel launches new Syria strikes amid Druze tensions
-
Finke grabs 400m medley victory over world record-holder Marchand
-
Apple eases App Store rules under court pressure
-
Polls open in Australian vote swayed by inflation, Trump
-
Russell clocks second fastest 100m hurdles in history at Miami meeting
-
Germany move against far-right AfD sets off US quarrel
-
Billionaire-owned Paris FC win promotion and prepare to take on PSG
-
Teenager Antonelli grabs pole for Miami sprint race
-
Man City climb to third as De Bruyne sinks Wolves
-
Mercedes' Wolff backs Hamilton to come good with Ferrari
-
'Devastated' Prince Harry says no UK return but seeks reconciliation
-
Elway agent death likely accidental: report
-
Turkish Cypriots protest new rule allowing hijab in school
-
Germany's AfD dealt blow with right-wing extremist label
-
Trump NASA budget prioritizes Moon, Mars missions over research
-
Hard-right romps through UK polls slapping aside main parties
-
Rangers hire two-time NHL champion Sullivan as coach
-
Haaland on bench for Man City as striker returns ahead of schedule
-
US designates two Haitian gangs as terror groups
-
Lower profits at US oil giants amid fall in crude prices
-
NBA icon Popovich stepping down as Spurs coach after 29 seasons
-
'Devastated' Prince Harry says no return to UK but seeks royal reconciliation
-
Grande scratched from Kentucky Derby
-
Carney vows to transform Canada economy to withstand Trump
-
Prince Harry says he would 'love' to reconcile with family
-
Major offshore quake causes tsunami scare in Chile, Argentina
-
GM cuts shift at Canada plant over 'evolving trade environment'
-
F1 extends deal to keep Miami GP until 2041
-
Popovich mixed toughness and spirit to make NBA history
-
US asks judge to break up Google's ad tech business
-
Trump eyes huge 'woke' cuts in budget blueprint
-
Ruud downs Cerundolo to book spot in Madrid Open final
-
Gregg Popovich stepping down as San Antonio Spurs coach after 29 seasons: team
-
Guardiola to take break from football when he leaves Man City
-
Vine escapes to Tour of Romandie 3rd stage win as Baudin keeps lead
-
Olympic 100m medalist Kerley arrested, out of Miami Grand Slam meet
-
Chile, Argentina order evacuations over post-quake tsunami threat
-
Arteta 'pain' as Arsenal fall short in Premier League title race
-
Hard-right romps across UK local elections slapping down main parties
-
US ends duty-free shipping loophole for low-cost goods from China
-
Renewables sceptic Peter Dutton aims for Australian PM's job

Hemogenyx Pharmaceuticals PLC Announces Final Results
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.
Key Highlights
The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.
Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.
Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.
Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.
http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
L.Harper--AMWN